BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading IMRX charts…

Search ticker or company⌘K

IMRX

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

IMRX · Immuneering Corp fundamentals · vpside

vpside

⌘K

IMRXMarket cap $242M/Last filing 10-Q · 29 Oct 2026/IMRXMarket cap $242M/Last filing 10-Q · 29 Oct 2026/IMRXMarket cap $242M/Last filing 10-Q · 29 Oct 2026/IMRXMarket cap $242M/Last filing 10-Q · 29 Oct 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

IMRX

Immuneering Corp

Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$0−100.0% year on year

$600000$400000$200000$0

vpside.com

Q3 ’21Q1 ’22Q4 ’22Q2 ’23Q4 ’23

Company filings · 10-K filed 1 Mar 2024 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

100.0%+72.0 pp year on year

100%75%50%25%

vpside.com

Q2 ’22Q3 ’22Q1 ’23Q2 ’23Q3 ’23

Company filings · 10-Q filed 9 Nov 2023 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$58M−74.4% year on year

$300M$200M$100M$0

vpside.com

Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26

Company filings · 10-Q filed 29 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$62M

$25M$0−$25M−$50M−$75M

vpside.com

Q3 ’22Q3 ’23Q3 ’24Q3 ’25Q3 ’26

Company filings · 10-Q filed 29 Oct 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters